Medios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany.
Solid track record with reasonable growth potential.
Share Price & News
How has Medios's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ILM1 has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ILM1 exceeded the German Healthcare industry which returned -2.6% over the past year.
Return vs Market: ILM1 exceeded the German Market which returned 3.4% over the past year.
Price Volatility Vs. Market
How volatile is Medios's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StHow Much Did Medios' (ETR:ILM1) CEO Pocket Last Year?
3 weeks ago | Simply Wall StWhat Can We Make Of Medios AG’s (ETR:ILM1) High Return On Capital?
1 month ago | Simply Wall StWith EPS Growth And More, Medios (ETR:ILM1) Is Interesting
Is Medios undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ILM1 (€36.2) is trading below our estimate of fair value (€53.16)
Significantly Below Fair Value: ILM1 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ILM1 is poor value based on its PE Ratio (54x) compared to the DE Healthcare industry average (25.8x).
PE vs Market: ILM1 is poor value based on its PE Ratio (54x) compared to the German market (20.9x).
Price to Earnings Growth Ratio
PEG Ratio: ILM1 is poor value based on its PEG Ratio (1.8x)
Price to Book Ratio
PB vs Industry: ILM1 is overvalued based on its PB Ratio (6.5x) compared to the DE Healthcare industry average (1.4x).
How is Medios forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ILM1's forecast earnings growth (30.1% per year) is above the savings rate (0.2%).
Earnings vs Market: ILM1's earnings (30.1% per year) are forecast to grow faster than the German market (22.4% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ILM1's revenue (15.4% per year) is forecast to grow faster than the German market (6% per year).
High Growth Revenue: ILM1's revenue (15.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ILM1's Return on Equity is forecast to be low in 3 years time (13.1%).
How has Medios performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ILM1 has high quality earnings.
Growing Profit Margin: ILM1's current net profit margins (1.9%) are higher than last year (1.3%).
Past Earnings Growth Analysis
Earnings Trend: ILM1's earnings have grown significantly by 70.9% per year over the past 5 years.
Accelerating Growth: ILM1's earnings growth over the past year (125.6%) exceeds its 5-year average (70.9% per year).
Earnings vs Industry: ILM1 earnings growth over the past year (125.6%) exceeded the Healthcare industry 9.7%.
Return on Equity
High ROE: ILM1's Return on Equity (12%) is considered low.
How is Medios's financial position?
Financial Position Analysis
Short Term Liabilities: ILM1's short term assets (€79.4M) exceed its short term liabilities (€28.7M).
Long Term Liabilities: ILM1's short term assets (€79.4M) exceed its long term liabilities (€6.3M).
Debt to Equity History and Analysis
Debt Level: ILM1's debt to equity ratio (3.6%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if ILM1's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: ILM1's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: ILM1's interest payments on its debt are well covered by EBIT (82.1x coverage).
What is Medios's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ILM1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ILM1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ILM1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ILM1's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ILM1's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Manfred Schneider (58yo)
Mr. Manfred Schneider has been the Chief Executive Officer and Chairman of the Executive Board at Medios AG since October 14, 2016. Mr. Schneider is the Founder of Medios Pharma GmbH and Medios Manufaktur ...
CEO Compensation Analysis
Compensation vs Market: Manfred's total compensation ($USD259.19K) is below average for companies of similar size in the German market ($USD1.31M).
Compensation vs Earnings: Manfred's compensation has increased by more than 20% in the past year.
|Chairman of Executive Board & CEO||3.75yrs||€227.00k||no data|
|CFO & Member of Executive Board||3.75yrs||€239.00k||no data|
|Chief Innovation Officer & Member of Executive Board||1.5yrs||€185.00k||no data|
|COO & Member of Executive Board||3yrs||€245.00k||no data|
Experienced Management: ILM1's management team is considered experienced (3.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.4%.
Medios AG's company bio, employee growth, exchange listings and data sources
- Name: Medios AG
- Ticker: ILM1
- Exchange: XTRA
- Founded: 2016
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: €582.277m
- Shares outstanding: 16.08m
- Website: https://www.medios.ag
Number of Employees
- Medios AG
- Friedrichstrasse 113a
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ILM1||DB (Deutsche Boerse AG)||Yes||Bearer Shares||DE||EUR||Aug 2016|
|ILM1||XTRA (XETRA Trading Platform)||Yes||Bearer Shares||DE||EUR||Aug 2016|
|0QB4||LSE (London Stock Exchange)||Yes||Bearer Shares||GB||EUR||Aug 2016|
Medios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products focusing on oncology, auto immunology, ophthalmology, and neurology, as well as infectious diseases. The Patient-Specific Therapies segment manufactures drugs for patients on behalf of pharmacies. The company was founded in 2016 and is headquartered in Berlin, Germany.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/15 20:56|
|End of Day Share Price||2020/07/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.